HC Wainwright Rates Gossamer Bio (GOSS) buy, $2 Price Target

HC Wainwright maintains its buy rating for GOSS with a $2 price target, a 1083.43% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 1:03 PM EDT · Updated Jun 26, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Gossamer Bio, Inc. ($GOSS) "buy" with a $2 price target on June 25, 2026.

Since the rating, $GOSS is up 4.8% after 1 week, up 20.6% after 1 month and down 33.6% to date (from the $13.20 close on Jun 25, 2026).

GOSS Gossamer Bio, Inc.

$8.77 -96.19% year to date

Daily close · Oct 16, 2026

Key Points

On June 25, 2026, HC Wainwright reiterated its buy rating on GOSS, setting a price target of $2.
HC Wainwright's $2 price target implies 1083.43% upside from Gossamer Bio, Inc.'s ($GOSS) current $0.17 share price.
Shares of GOSS traded near $0.17 on Thursday, reflecting the company's current market conditions.
Several insiders, including Daniel Thomas and Quisel John, each acquired 115,000 shares on June 4, 2026.

Get $GOSS trade alerts by text

We text you when insiders, Congress or big funds trade $GOSS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Gossamer Bio, Inc. alert may contain errors. Disclosures

HC Wainwright has reiterated its buy rating on GOSS, setting a price target of $2. The analyst, Patrick R. Trucchio, confirmed this stance on June 25, 2026. The stock traded near $0.17 on Thursday.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +48.71% hypothetical

All-time return +147.57% S&P 500 +26.79%

vs. S&P 500 +120.78% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in GOSS

BlackRock, Inc. reduced its holdings in GOSS by 230,183 shares, leaving it with 16,826,695 shares valued at about $5.53 million, a 1.3% decrease. Kalehua Capital Management LLC opened a new position with 10,236,293 shares worth approximately $3.36 million. AQR Capital Management LLC significantly increased its stake by 9,007,657 shares, resulting in a total of 10,126,897 shares valued at $3.33 million, marking an 804.8% increase. Vanguard Capital Management LLC also initiated a new position, acquiring 9,394,593 shares worth about $3.09 million. Meanwhile, Octagon Capital Advisors LP cut its holdings by 6,165,371 shares, ending with 7,750,000 shares valued at $2.55 million, a 44.3% decrease.

Insider Buying and Selling at Gossamer Bio, Inc.

On June 4, 2026, several insiders at GOSS, including Daniel Thomas, John Quisel, Steven Nathan, Russell Cox, Skye Drynan, and Sandra Milligan, each purchased 115,000 shares. These transactions were not part of a pre-planned trading scheme.

Analysts Set New Price Targets

On June 25, 2026, HC Wainwright & Co. maintained its buy rating on GOSS with a $2 price target. Previously, on May 19, 2026, Barclays maintained a sell rating with a $0.28 target. Earlier this year, on March 6, 2026, HC Wainwright & Co. had also maintained a buy rating with a higher target of $5.

Bottom Line

HC Wainwright's reiterated buy rating and $2 target suggest confidence in GOSS's prospects. Institutional investors and insiders have shown varied interest, with some increasing positions while others reduced or initiated new stakes. As always, these ratings and transactions reflect past decisions and may not indicate future performance.

12-month forecast